Condition
Astrocytoma, Grade II
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
3 terminated out of 6 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed3
Terminated3
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07673666Completed
GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)
NCT02549833Phase 1Completed
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
NCT04304300CompletedPrimary
Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes
NCT02924038Phase 1Terminated
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT03906448Phase 2TerminatedPrimary
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
NCT01836549Phase 2Terminated
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Showing all 6 trials